Fmr LLC Grows Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Fmr LLC raised its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 25.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,739 shares of the biopharmaceutical company’s stock after buying an additional 30,802 shares during the quarter. Fmr LLC’s holdings in Vanda Pharmaceuticals were worth $702,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of VNDA. Nantahala Capital Management LLC boosted its position in shares of Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after acquiring an additional 580,265 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after purchasing an additional 292,172 shares during the last quarter. Monaco Asset Management SAM purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $1,090,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $864,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 7.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock worth $3,663,000 after buying an additional 55,567 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on VNDA shares. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, December 11th. They issued a “hold” rating on the stock. HC Wainwright started coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective on the stock.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Stock Up 2.2 %

Vanda Pharmaceuticals stock opened at $4.73 on Wednesday. The firm has a fifty day moving average of $4.85 and a 200-day moving average of $5.23. Vanda Pharmaceuticals Inc. has a 52-week low of $3.46 and a 52-week high of $6.75. The firm has a market capitalization of $275.80 million, a P/E ratio of -16.54 and a beta of 0.76.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.